The BC Renal Agency provides restricted funding for Sevelamer HCL (Renagel) and Lanthanum Carbonate (Fosrenol) for the prevention of secondary hyperparathyroidism and risk of parathyroidectomy.
Funding is restricted on the basis that outcomes research available at this time does not firmly establish the benefits of this medication for indications other than preventing secondary hyperparathyroidism and risk of parathyroidectomy.
We are aware of the risks of calcification, but cannot justify expanded use of this agent based on the evidence available and prohibitive cost. Should new research or cost utility studies be published defining a benefit in other patients, we would welcome another review. (Please note that patients do have the option to pay for the medication themselves if it is considered to be indicated in other clinical circumstances.)
A guiding principle used by BCPRA in funding medications is proven efficacy for specific indications, as demonstrated through long-term outcome measures research. This principle ensures we are directing limited financial resources to the medications that have the greatest benefit for renal patients across the province.
SEVELAMER OR LANTHANUM CRITERIA AND APPLICATION FORMS
Please note that the forms require the signatures of both (a) the nephrologist or renal clinical pharmacist, and (b) the renal dietitian (confirming dietary compliance).
Please also note the following guidelines on prescription quantities and refills.